FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 22 of 34
Apr 13, 2026The proposed budget for 2027 includes substantial reductions in healthcare spending, which experts warn could jeopardize patient care and biomedical research. This article explores the broader implications of the proposal and reactions from leaders in healthcare policy.
Daniel Cho
Apr 12, 2026This year, the DOJ filed lawsuits against major health systems like OhioHealth and NewYork-Presbyterian Hospital, alleging the use of all-or-nothing contracts that limit market competition and keep insurance prices elevated. This crackdown highlights regulatory efforts to ensure fair contracting practices that benefit patients and insurers alike by fostering transparency and competition in hospital networks.
Emily Carter
Apr 11, 2026Nutrition education in medical school remains a topic of public debate, raising questions about its adequacy and role in prevention care. Diverse opinions challenge assumptions and call for deeper analysis of educational impacts on healthcare outcomes.
Jonathan Blake
Apr 11, 2026The expansion of sports betting has created a complex public health challenge, intertwining addiction issues with mental health concerns for some demographics. Experts suggest that the culture around gambling may be fostering increased risk and negative societal effects.
Sophia Reynolds
Apr 10, 2026Replimune's RP1, an advanced melanoma therapeutic candidate, faces a significant regulatory setback as the FDA reiterates its objection to the clinical trial methodology. This decision highlights ongoing challenges in gaining approval for innovative oncology treatments through non-randomized trials.
Jonathan Blake
Apr 10, 2026After discontinuing Wellcovorin in 1999, GSK faced a renewed FDA request late last year to refile an application due to leucovorin’s possible efficacy in managing autistic features linked to cerebral folate deficiency. This post explores the drug’s regulatory journey, scientific rationale, and the broader implications for autism treatment development.
Jonathan Blake
Apr 10, 2026Following a recent court ruling on April 7, 2026, the FDA faces renewed pressure to finalize its internal safety assessment of mifepristone, a medication widely used for abortion services. The court’s decision preserves mail access for the drug, highlighting the complex regulatory and legal landscape influencing medication abortion availability in the U.S.
Dr. Priya Nandakumar
Apr 9, 2026As health care costs continue their upward trajectory, a prominent Democratic think tank has introduced an ambitious plan to tackle affordability. This blueprint aims to reshape health policy by addressing key cost drivers and proposing actionable reforms. The move signals a strategic push by Democrats to prioritize health care affordability ahead of forthcoming political contests, reflecting growing public demand for accessible and sustainable health services.
Dr. Priya Nandakumar
Apr 9, 2026After facing criticism over cumbersome prior authorization procedures, health insurers have committed to reforms that are already yielding noticeable reductions. This article explores the extent of these changes, what they mean for patient care, and ongoing efforts by organizations such as AHIP and the Blue Cross Blue Shield Association to further enhance efficiencies in the health system.
Daniel Cho
Apr 9, 2026Recent data highlight that the highest and lowest health spending metros in the United States do not follow a predictable pattern. Experts suggest that this randomness points to systemic inefficiencies and irrationalities in U.S. health care spending. This article delves into the details of this phenomenon and its implications for health policy and cost control.
Daniel Cho
Apr 8, 2026The judge's ruling maintains access to mifepristone through mail-order prescriptions for now, reflecting the complex regulatory landscape surrounding abortion medication. The FDA’s review may influence future policy decisions and availability.
Daniel Cho
Apr 7, 2026With a focus on accelerating pharmaceutical innovation and enhancing public health, the FDA plans to make rare disease vouchers a permanent program and facilitate easier clinical entry for new therapeutics. These changes aim to support faster development pathways for treatments addressing rare and complex conditions.
Michael TorresMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.